Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ben Tre Pharmaceutical JSCSTC:DBT 13 Debt-to-Equity is 0.00 as of . 20. GuruFocus rates STC:DBT with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 811 Drug Manufacturers companies, Ben Tre Pharmaceutical JSC ranks worse than 123304.44% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ben Tre Pharmaceutical JSC's Debt-to-Equity or its related term are showing as below:
STC:DBT's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27 * Ranked among companies with meaningful Debt-to-Equity only.
Ben Tre Pharmaceutical JSC (STC:DBT) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Ben Tre Pharmaceutical JSC Debt-to-Equity Related Terms
Ben Tre Pharmaceutical JSC Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Tre Pharmaceutical JSC Debt-to-Equity Chart
Ben Tre Pharmaceutical JSC Annual Data
Trend
Debt-to-Equity
Ben Tre Pharmaceutical JSC Semi-Annual Data
Debt-to-Equity
STC:DBT vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Ben Tre Pharmaceutical JSC's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ben Tre Pharmaceutical JSC Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ben Tre Pharmaceutical JSC's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ben Tre Pharmaceutical JSC's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ben Tre Pharmaceutical JSC (STC:DBT) has a Debt-to-Equity of 0.00 as of . 20. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ben Tre Pharmaceutical JSC and its competitors. According to the industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 811 companies in the Drug Manufacturers industry.
Is Ben Tre Pharmaceutical JSC's Debt-to-Equity too high?
Ben Tre Pharmaceutical JSC's current Debt-to-Equity is 0.00. Based on the distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 811 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ben Tre Pharmaceutical JSC has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Ben Tre Pharmaceutical JSC's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ben Tre Pharmaceutical JSC ranks #999999 out of 811 companies for Debt-to-Equity. This places Ben Tre Pharmaceutical JSC in the lower half of its industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Ben Tre Pharmaceutical JSC and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ben Tre Pharmaceutical JSC's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ben Tre Pharmaceutical JSC stock overvalued right now?
Ben Tre Pharmaceutical JSC (STC:DBT) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Ben Tre Pharmaceutical JSC's overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Ben Tre Pharmaceutical JSC (STC:DBT), the current Debt-to-Equity is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ben Tre Pharmaceutical JSC is based in Vietnam. The company is engaged in trading in pharmaceuticals, functional foods, vaccines, cosmetics, medical equipment, & medical machinery. It is also engaged in the Import and export of testing chemicals & biological products, Manufacturing medicines for human treatment, producing pharmaceuticals, chemicals, and medicinal herbs, and Leasing warehouses and premises.
13GF Score
Get the complete analysis for STC:DBT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:DBT has been successfully added to your 
